Campbell JM

Deenen MJ

Dorothy M Keefe

Emma Bateman

Furuta T

Jared M Campbell

Joanne M Bowen

Lee A

Levy E

Mandola MV

Matthew D Stephenson

Micah DJ Peters

Papanastasopoulos P

Pinedo HM

Stojanovska V

Tepper JE

Van Kuilenburg AB

Zhang QA

 Fluoropyrimidine (FU) and platinum-based chemotherapies are greatly complicated by their associated toxicities. This umbrella systematic review synthesized all systematic reviews that investigated associations between germline variations and toxicity, with the aim of informing personalized medicine. Systematic reviews are important in pharmacogenetics where false positives are common. Four systematic reviews were identified for FU-induced toxicity and three for platinum. Polymorphisms of DPYD and TYMS, but not MTHFR, were statistically significantly associated with FU-induced toxicity (although only DPYD had clinical significance). For platinum, GSTP1 was found to not be associated with toxicity. This umbrella systematic review has synthesized the best available evidence on the pharmacogenetics of FU and platinum toxicity. It provides a useful reference for clinicians and identifies important research gaps. </jats:p

Crossref

Pharmacogenomics

Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

Abstract

Similar works

Full text

Available Versions

Crossref